稳心颗粒联合胺碘酮治疗冠心病心律失常的疗效

Efficacy of treating coronary heart arrhythmia with the Wenxin granule and amiodarone

目的:探讨稳心颗粒联合胺碘酮治疗冠心病(CAD)心律失常的疗效和用药安全性。方法:运用系统评价的方法,全面检索近两年来来自万方数据库的相关文献以及所获文献的参考文献。初步筛选其中随机对照的试验方法纳入研究,对纳入研究逐个进行质量评价和筛选,而后对其进行系统评价。结果:共20个研究(1638例)符合纳入标准,其中有15篇文献对其临床疗效和安全性进行了观测,共计1306例患者作为系统评价的对象,治疗组的疗效和安全性均优于对照组,其差异有统计学意义(P<0.05)。结论:现有的临床证据表明,稳心颗粒联合胺碘酮治疗冠心病心律失常有效,安全性较高,但本研究所纳入试验的方法学质量较低,试验病例数太少,且观察时间过短,没有对药物的安全性、患者的长期预后及病死率进行深入的研究,因此,进行高质量、大样本、长期随访的随机对照试验非常必要。

Objective: To explore safety and efficacy of the Wenxin granule and amiodarone on CAD. Methods: Relevant literature in nearly two years were searched from WanFang data base. Results: A total of 20 studies (1638 patients) met the inclusion criteria, of which 15 documents the clinical efficacy and safety were observed, patients with a total of 1306 cases as the object of systematic reviews. The efficacy and safety of the treatment group was better than the control group. The difference was statistically significant (P<0.05). Conclusion: Existing clinical evidence that Wenxin granule amiodarone effective apply in treating coronary heart arrhythmia, with high security; But lower in this study methodological quality of the included trials, too few test cases, and the observation time is too short and no drug safety, long-term prognosis and mortality in patients with in-depth study. Therefore, high-quality, large-sample, long-term follow-up of a randomized controlled trial is necessary.